Skip to main content
Premium Trial:

Request an Annual Quote

Amgen Layoffs

Amgen is laying off 380 people from its research and development division, reports Fierce Biotech. The layoffs will be mainly in the US, with 226 people being let go from the company's Thousand Oaks location, with others from Seattle, South San Francisco, Boston, and possibly in the UK. Fierce Biotech notes that while the layoffs represent 2 percent of the company's overall workforce, they are 6 percent of its R&D staff. "These are very targeted and strategic reductions so we can continue to allocate our R&D resources in a focused manner," says Amgen spokesperson Mary Klem, according to Reuters.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.